A Phase 3 interventional study of TNX-102 SL in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Terminated at 32 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 265th largest by enrollment of the 1,491 interventional ones that give a count, is one of 74 that started in 2017, is one of 64 in phase 3, and was the 755th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 603 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Anthony Vesco · Sites in United States
Ages 8–18
Transcend Therapeutics · Sites in United States
Ages 18+
COMPASS Pathways · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,664 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 132 · Phase 2 234 · Phase 3 95 · Phase 4 90
First in 1991; this study’s year is marked. 74 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 69 across 2,199 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 1,491 interventional studies, 107 across the 165 observational. Of the 1,135 that completed or were terminated, 491 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 1,664 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 7 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
154 of the studies in Stress Disorders, Post-Traumatic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT04877093Phase 3Wake Forest University Health SciencesRepurposing Low-Dose Clonidine for PTSD in Veterans | 2027-03-31 |
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT07217795University of Rhode IslandRecovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building | 2026-11 |
| NCT04585685Christal L BadourHealthy Recovery After Trauma Study | 2026-11 |
Add all 154 to your calendar (.ics) → With an account.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited into this trial are those who have successfully completed the double-blind lead-in study.
The study will consist of 5 study visits, including Screening/Baseline Visit 1 (Day 0, which is anticipated to be the same visit as the last visit on double-blind treatment), a phone visit after 2 weeks of treatment, and in-clinic visits after 4, 8, and 12 weeks of treatment.
The primary objective of the study is to evaluate the safety of TNX-102 SL tablets taken daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a double-blinded lead-in study.
The secondary objective of the study is to evaluate the efficacy of TNX-102 SL tablets taken daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a double-blinded lead-in study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
Drug: TNX-102 SL
2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
Also known as: cyclobenzaprine HCl
Incidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study
Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class.
Time frame: 12 weeks
Change From Both Baselines in the Total Clinician Administered PTSD Scale for DSM-5 (CAPS-5) Score
The CAPS-5 symptom severity 1-week recall version will be administered by qualified and trained clinicians. Score ranges from 0 to 80 with lower scores indicating less severe PTSD symptoms.
Time frame: Day 1 of TNX-CY-P301 (Week -12 of TNX-CY-P303), Day 1 of TNX-CY-P303, Week 12 of TNX-CY-P303
| Milestone | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL |
|---|---|---|
| Started | 97 | 93 |
| Completed | 68 | 67 |
| Not completed | 29 | 26 |
Adverse events will be coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and will be summarized overall and by preferred term and system organ class.
| Participants | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL |
|---|---|---|
| Incidence of Newly Emergent Adverse Events of TNX-102 SL Tablets Taken Daily at Bedtime Over an Additional 12 Weeks in Patients With PTSD Who Have Completed a Double-blinded lead-in Study | 62 | 40 |
The CAPS-5 symptom severity 1-week recall version will be administered by qualified and trained clinicians. Score ranges from 0 to 80 with lower scores indicating less severe PTSD symptoms.
| units on a scale | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL |
|---|---|---|
| Change from TNX-CY-P301 baseline | -24.5 ± 2.43 | -24.2 ± 2.64 |
| Change from TNX-CY-P303 baseline | -6.2 ± 1.63 | -6.2 ± 1.78 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - TNX-102 SL | 0/97 (0%) | 0/97 (0%) | 49/97 (50.5%) |
| TNX-102 SL - TNX-102 SL | 0/93 (0%) | 0/93 (0%) | 19/93 (20.4%) |
| Event | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL |
|---|---|---|
| Hypoaesthesia OralGastrointestinal disorders | 29/97 | 12/93 |
| GlossodyniaGastrointestinal disorders | 9/97 | 2/93 |
| SomnolenceNervous system disorders | 9/97 | 8/93 |
| Paraesthesia oralGastrointestinal disorders | 7/97 | 2/93 |
| Product Taste AbnormalProduct Issues | 6/97 | 4/93 |
| Age, Continuous(years) | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL | Total |
|---|---|---|---|
| Mean | 36.5 ± 8.19 | 36.1 ± 7.85 | 36.3 ± 8.01 |
| Sex: Female, Male(Participants) | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL | Total |
|---|---|---|---|
| Female | 15 | 6 | 21 |
| Male | 82 | 87 | 169 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL | Total |
|---|---|---|---|
| Hispanic or Latino | 18 | 16 | 34 |
| Not Hispanic or Latino | 79 | 77 | 156 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 4 | 6 |
| Asian | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 5 |
| Black or African American | 17 | 22 | 39 |
| White | 64 | 56 | 120 |
| More than one race | 5 | 2 | 7 |
| Unknown or Not Reported | 2 | 4 | 6 |
| Region of Enrollment(participants) | Placebo - TNX-102 SL | TNX-102 SL - TNX-102 SL | Total |
|---|---|---|---|
| United States | 97 | 93 | 190 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jun 2017 to primary completion in Jul 2018, 13 months.
Results were first posted in Feb 2025, 6 years 6 months after primary completion. A results delay was requested in Sep 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine
Stress Disorders, Post-Traumatic →